TIANDA PHARMA (00455) announced its performance for the year 2025, with a net loss attributable to shareholders of HK$69.997 million, an increase of 14.1% year-on-year.

TIANDA PHARMA (00455) announced its annual performance for the year ending December 31, 2025, with revenue of 323 million Hong Kong dollars, a decrease of 2.1% year-on-year; the company's attributable loss to shareholders was 69.997 million Hong Kong dollars, an increase of 14.1% year-on-year; basic loss per share was 3.26 Hong Kong cents. The group actively optimized its sales strategy and promoted resource integration, effectively enhancing overall risk resistance. During the period, due to the recurring impact of respiratory infections in mainland China, the market demand for the group's pediatric drug Ton ibuprofen increased, driving revenue growth. In the first half of 2025, Ton ibuprofen ranked second in market share among similar products in mainland China. Meanwhile, another core product - Topping valsartan capsules for cardiovascular and cerebrovascular diseases, was affected by China's centralized drug procurement policy and bidding mechanism, which resulted in a decrease in sales volume.